Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yvonne Huckleberry is active.

Publication


Featured researches published by Yvonne Huckleberry.


Pharmacotherapy | 2006

Pharmacologic Management of Constipation in the Critically Ill Patient

Asad E. Patanwala; Jacob Abarca; Yvonne Huckleberry; Brian L. Erstad

Study Objective. To compare the effectiveness of common laxatives in producing a bowel movement in patients admitted to a medical intensive care unit (MICU).


Journal of Pharmacy Practice | 2013

Evaluation of Discontinuation of Atypical Antipsychotics Prescribed for ICU Delirium

Karalea D. Jasiak; Ellen A. Middleton; James M. Camamo; Brian L. Erstad; Linda Snyder; Yvonne Huckleberry

A number of trials suggest that short-term use of atypical antipsychotics may be useful in the treatment of delirium associated with critical illness. However, long-term use of such agents for this indication has not been studied and may be associated with risks of adverse effects as well as unnecessary health care costs. A retrospective study of prescribing patterns of atypical antipsychotics initiated for the treatment of intensive care unit (ICU) delirium was performed to identify whether these agents were being discontinued prior to or upon hospital discharge. Of the 59 patients who met inclusion criteria and survived to hospital discharge, 28 (47%) were continued on the atypical antipsychotic upon discharge from the medical ICU. For those continued on the agent, 20 patients (71.4%) were prescribed continued therapy as an outpatient. Inpatient costs for atypical antipsychotics during the 9-month study period were increased by approximately


Respiratory Care | 2014

Non-cardiogenic pulmonary edema and life-threatening shock due to calcium channel blocker overdose: a case report and clinical review.

Tauseef Afaq Siddiqi; Jennifer Hill; Yvonne Huckleberry; Sairam Parthasarathy

888. Annual cost of the medication as outpatient therapy is assessed at approximately


American Journal of Critical Care | 2012

Effect of Albumin on Diuretic Response to Furosemide in Patients With Hypoalbuminemia

Thitima Doungngern; Yvonne Huckleberry; John W. Bloom; Brian L. Erstad

45 107. Although short-term trials of atypical antipsychotics may be useful for ICU delirium, caution is advised regarding potential adverse effects and added health care costs when use is prolonged.


Blood | 2016

Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States

Ahmed Aljabri; Yvonne Huckleberry; Jason H. Karnes; Mahdi Gharaibeh; Hussam Kutbi; Yuval Raz; Seongseok Yun; Ivo Abraham; Brian L. Erstad

Calcium channel blockers (CCBs) overdose can be life-threatening when manifest as catastrophic shock and non-cardiogenic pulmonary edema. We describe a case of massive overdose of multiple medications, including sustained-release verapamil, which was resistant to conventional support. Initial treatment for CCB overdose is primarily supportive, and includes fluid resuscitation. The mechanism of non-cardiogenic pulmonary edema is not well known, and reported cases have been successfully treated with mechanical ventilation. Circulatory shock may fail to respond to atropine, glucagon, and calcium in severely poisoned patients, and vasopressors are usually required. Attempting to overcome calcium-channel antagonism with the supra-therapeutic doses of calcium salts is clinically indicated to reverse hypotension and bradycardia. There is evidence that hyperinsulinemia-euglycemia therapy is superior to other therapies for CCB poisoning, and the mechanism is thought to be the insulin-mediated active transport of glucose into the cells, which counters the CCB-induced intra-cellular carbohydrate-deficient state. Conventional decontamination measures are ineffective in accelerating clearance of CCB. Experience with intravenous lipid emulsion for lipophilic drug overdose, such as verapamil, is limited, but has been proposed as a rescue therapy and might improve cardiac inotropy through intravascular sequestration of the lipophilic CCB.


Journal of Critical Care | 2014

Cost savings with interventions to reduce aerosolized bronchodilator use in mechanically ventilated patients

James M. Camamo; Kurt Weibel; Terence O’Keeffe; Yvonne Huckleberry; Brian J. Kopp; Conrad Diven; Brian L. Erstad

BACKGROUND Albumin is broadly prescribed for critically ill patients although it does not have a mortality benefit over crystalloids. One common use of albumin is to promote diuresis. Objectives To compare urine output in patients treated with furosemide with and without albumin and to assess other variables possibly associated with enhanced diuresis. METHODS A retrospective study was conducted on patients in a medical intensive care unit who received furosemide therapy as a continuous infusion with and without 25% albumin for more than 6 hours. Primary end points were urine output and net fluid loss. RESULTS A total of 31 patients were included in the final analysis. Mean urine output in patients treated with furosemide alone did not differ significantly from output in patients treated with furo-semide plus albumin at 6, 24, and 48 hours: mean output, 1119 (SD, 597) mL vs 1201 (SD, 612) mL, P = .56; 4323 (SD, 1717) mL vs 4615 (SD, 1741) mL, P = .42; and 7563 mL (SD, 2766) vs 7432 (SD, 2324) mL, P = .94, respectively. Additionally, net fluid loss did not differ significantly between the 2 groups at 6, 24, and 48 hours. Higher concentrations of serum albumin did not improve urine output. The only independent variable significantly associated with enhanced urine output at 24 and 48 hours was increased fluid intake. CONCLUSION Addition of albumin to a furosemide infusion did not enhance diuresis obtained with furosemide alone in critically ill patients.


Clinical Toxicology | 2018

Incidence of allergic reactions to Crotalidae polyvalent immune Fab

Moteb Khobrani; Yvonne Huckleberry; Keith Boesen; Ahmed Aljabri; Mobarak Alharthi; Asad E. Patanwala

Despite the availability of multiple nonheparin anticoagulants for the treatment of heparin-induced thrombocytopenia (HIT), few data are available comparing the cost-effectiveness of these agents. This analysis is particularly important when considering differences in the risk of adverse effects, routes of administration, requirements for phlebotomy and laboratory monitoring, and overall drug costs. We conducted a cost-effectiveness analysis of argatroban, bivalirudin, and fondaparinux for the treatment of suspected HIT from the institutional perspective. A 3-arm decision-tree model was developed that employs standard practices for anticoagulation monitoring. We incorporated published data on drug efficacy and probability of HIT-related thromboembolism and major bleeding. We considered both institutional costs and average wholesale price (AWP) and performed probabilistic sensitivity analyses (PSA) to address any uncertainty in model parameters. Using institutional costs, fondaparinux prevailed over both argatroban and bivalirudin in terms of cost (


The American Journal of Medicine | 2017

Evaluation of Deprescribing Amiodarone After New-Onset Atrial Fibrillation in Critical Illness

Areerut Leelathanalerk; Wannisa Dongtai; Yvonne Huckleberry; Brian J. Kopp; John W. Bloom; Joseph S. Alpert

151 vs


BMC Blood Disorders | 2007

Impact of delayed initiation of erythropoietin in critically ill patients

Jeremiah John Duby; Brian L. Erstad; Jacob Abarca; James M. Camamo; Yvonne Huckleberry; Stuart N Bramblett

1250 and


American Journal of Health-system Pharmacy | 2004

Nutritional support and the surgical patient

Yvonne Huckleberry

1466, respectively) and adverse events averted (0.9989 vs 0.9957 and 0.9947, respectively). Results were consistent when AWP was used, with fondaparinux being less expensive (

Collaboration


Dive into the Yvonne Huckleberry's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge